PDF(Pubmed)
Abstract：
UNASSIGNED: Ulinastatin has been applied in a series of diseases associated with inflammation but its clinical effects remain somewhat elusive.
UNASSIGNED: We aimed to investigate the potential effects of ulinastatin on organ failure patients admitted to the intensive care unit (ICU).
UNASSIGNED: This is a single-center retrospective study on organ failure patients from 2013 to 2019. Patients were divided into two groups according to using ulinastatin or not during hospitalization. Propensity score matching was applied to reduce bias. The outcomes of interest were 28-day all-cause mortality, length of ICU stay, and mechanical ventilation duration.
UNASSIGNED: Of the 841 patients who fulfilled the entry criteria, 247 received ulinastatin. A propensity-matched cohort of 608 patients was created. No significant differences in 28-day mortality between the two groups. Sequential organ failure assessment (SOFA) was identified as the independent risk factor associated with mortality. In the subgroup with SOFA ≤ 10, patients received ulinastatin experienced significantly shorter time in ICU (10.0 d [interquartile range, IQR: 7.0∼20.0] vs 15.0 d [IQR: 7.0∼25.0]; p = .004) and on mechanical ventilation (222 h [IQR:114∼349] vs 251 h [IQR: 123∼499]; P = .01), but the 28-day mortality revealed no obvious difference (10.5% vs 9.4%; p = .74).
UNASSIGNED: Ulinastatin was beneficial in treating patients in ICU with organ failure, mainly by reducing the length of ICU stay and duration of mechanical ventilation.
UNASSIGNED: We aimed to investigate the potential effects of ulinastatin on organ failure patients admitted to the intensive care unit (ICU).
UNASSIGNED: This is a single-center retrospective study on organ failure patients from 2013 to 2019. Patients were divided into two groups according to using ulinastatin or not during hospitalization. Propensity score matching was applied to reduce bias. The outcomes of interest were 28-day all-cause mortality, length of ICU stay, and mechanical ventilation duration.
UNASSIGNED: Of the 841 patients who fulfilled the entry criteria, 247 received ulinastatin. A propensity-matched cohort of 608 patients was created. No significant differences in 28-day mortality between the two groups. Sequential organ failure assessment (SOFA) was identified as the independent risk factor associated with mortality. In the subgroup with SOFA ≤ 10, patients received ulinastatin experienced significantly shorter time in ICU (10.0 d [interquartile range, IQR: 7.0∼20.0] vs 15.0 d [IQR: 7.0∼25.0]; p = .004) and on mechanical ventilation (222 h [IQR:114∼349] vs 251 h [IQR: 123∼499]; P = .01), but the 28-day mortality revealed no obvious difference (10.5% vs 9.4%; p = .74).
UNASSIGNED: Ulinastatin was beneficial in treating patients in ICU with organ failure, mainly by reducing the length of ICU stay and duration of mechanical ventilation.
摘要：
乌司他丁已应用于一系列与炎症相关的疾病，但其临床效果仍然有些难以捉摸。
■我们旨在研究乌司他丁对重症监护病房（ICU）收治的器官衰竭患者的潜在影响。
■这是一项针对2013年至2019年器官衰竭患者的单中心回顾性研究。根据住院期间是否使用乌司他丁分为两组。倾向评分匹配用于减少偏倚。感兴趣的结果是28天全因死亡率，ICU住院时间,和机械通气持续时间。
■在841名符合入选标准的患者中，247人接受了乌司他丁。创建了608名患者的倾向匹配队列。两组28天死亡率无显著差异。序贯器官衰竭评估（SOFA）被确定为与死亡率相关的独立危险因素。在SOFA≤10的亚组中，接受乌司他丁的患者在ICU中的时间明显缩短（10.0d[四分位数范围，IQR：7.0〜20.0]vs15.0d[IQR：7.0〜25.0]；p=.004）和机械通气（222h[IQR：114〜349]vs251h[IQR：123〜499]；P=.01），但28天死亡率无明显差异(10.5%vs9.4%;p=0.74)。
■乌司他丁对ICU器官衰竭患者的治疗有益，主要通过减少ICU住院时间和机械通气时间。
■我们旨在研究乌司他丁对重症监护病房（ICU）收治的器官衰竭患者的潜在影响。
■这是一项针对2013年至2019年器官衰竭患者的单中心回顾性研究。根据住院期间是否使用乌司他丁分为两组。倾向评分匹配用于减少偏倚。感兴趣的结果是28天全因死亡率，ICU住院时间,和机械通气持续时间。
■在841名符合入选标准的患者中，247人接受了乌司他丁。创建了608名患者的倾向匹配队列。两组28天死亡率无显著差异。序贯器官衰竭评估（SOFA）被确定为与死亡率相关的独立危险因素。在SOFA≤10的亚组中，接受乌司他丁的患者在ICU中的时间明显缩短（10.0d[四分位数范围，IQR：7.0〜20.0]vs15.0d[IQR：7.0〜25.0]；p=.004）和机械通气（222h[IQR：114〜349]vs251h[IQR：123〜499]；P=.01），但28天死亡率无明显差异(10.5%vs9.4%;p=0.74)。
■乌司他丁对ICU器官衰竭患者的治疗有益，主要通过减少ICU住院时间和机械通气时间。
